Mucopolysaccharidosis Type IIIB Clinical Trial
Official title:
Natural History Studies of Mucopolysaccharidosis III
The purpose of this study is to assess rates of decline in motor and cognitive functional measures, and to assess potential biomarkers, in order to identify potential outcome measure appropriate for use in therapeutic clinical trials.
Mucopolysaccharidosis (MPS) type III (Sanfilippo syndrome) is a group of four devastating
genetic diseases that result in the abnormal accumulation of glycosaminoglycans in body
tissues. In MPSIII the predominant symptoms occur due to accumulation within the central
nervous system (CNS), including the brain and spinal cord, resulting in cognitive decline,
motor dysfunction, and eventual death.
In anticipation for future therapeutic studies for MPSIIIA and MPSIIIB, we are performing a
natural history study to identify the following:
1. Individual rates of decline in motor and cognitive function in a cohort of potential
clinical trial patients
2. The natural history of outcome measures in order to assess their appropriateness as
outcomes in an eventual trial
3. Baseline functional data in patients who will be potential candidates for an eventual
trial
4. Biomarkers of disease progression over a 12-month interval, including changes in brain
MRI and in cerebrospinal fluid
Patients in this study will need to come to Nationwide Children's Hospital in Columbus,
Ohio, three times. At each of these three time points, cognitive outcome measures will be
assessed: at baseline (visit 1), 6 months (visit 2), and at 12 months (visit 3). At baseline
(visit 1) and 12 months (visit 3), an MRI and a lumbar puncture will be performed.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02493998 -
A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)
|
||
Active, not recruiting |
NCT03227042 -
A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)
|
||
Active, not recruiting |
NCT03784287 -
A Treatment Extension Study of Mucopolysaccharidosis Type IIIB
|
Phase 2 | |
Completed |
NCT02754076 -
A Treatment Study of Mucopolysaccharidosis Type IIIB
|
Phase 1/Phase 2 |